Andrzej Patyra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Andrzej Patyra has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Anna Karolina Kiss
Chair and Department of Pharmaceutical Biology, Medical University of Warsaw, Banacha 1, 02-097 Warsaw, Poland
6 shared publications - Marta Katarzyna Dudek
Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland
3 shared publications - Catherine Oiry
IBMM, Univ Montpellier, CNRS, ENSCM Montpellier France
2 shared publications Jakub Olszewski
Student's Scientific Group, Medical Simulation Center, Medical University of Warsaw, 02-097 Warsaw, Poland
2 shared publications- Jérémie Neasta
IBMM, Univ Montpellier, CNRS, ENSCM Montpellier France
2 shared publications Katarzyna Kozon
Student's Scientific Group, Department of Nephrology, Dialysis and Internal Medicine, Medical University of War-saw, 02-097 Warsaw, Poland
2 shared publications
Latest Publications
- 5 June 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Effects and underlying mechanism of plant secondary metabolites on insulin secretion regulation
Effets et mécanisme d'action de métabolites secondaires des plantes sur la régulation de la sécrétion d’insuline: Le diabète de type 2 (DT2) est une maladie associant résistance à l'insuline et dysfonction des cellules β pancréatiques. Basées sur la compréhension actuelle de la physiopathologie de cette maladie, différentes approches thérapeutiques ont été développées afin d'améliorer le contrôle glycémique et de ralentir la progression de la maladie. Néanmoins, elles présentent une efficacité limitée et de nombreux effets indésirables. Dans ce contexte, les extraits végétaux et leurs constituants actifs sont considérés comme un domaine important pour la recherche de nouveaux traitements antidiabétiques. Cette thèse avait pour objectif de trouver une source naturelle de métabolites secondaires végétaux potentiellement capables de protéger la fonction des cellules β, d'induire la sécrétion d'insuline de façon gluco-dépendante, et de caractériser le mécanisme d'action des molécules actives. Vingt extraits de plantes ont été profilés phytochimiquement à l'aide de LC-MS, conduisant à l'identification et l'isolement de 39 composés purifiés. Les flavonoïdes, les lignanes et les coumarines ont été testés pour leur capacité à moduler la fonction des cellules β sur le modèle cellulaire INS-1. Certains flavonoïdes et coumarines ont augmenté la sécrétion d'insuline induite par le glucose, tandis qu'aucun effet n'a été observé avec les lignanes. Le mécanisme d'action des métabolites actifs a ensuite été étudié en évaluant leurs effets sur l'activité électrique des cellules, les niveaux de calcium intracellulaire et les courants calciques et potassiques. De plus, l'activité insulino-sécrétoire a été confirmée dans des extraits pharmacopéiques contenant des coumarines. Ces découvertes pourraient avoir des implications sur l'utilisation traditionnelle des racines d'angélique dans le traitement du DT2. Des effets insulinotropes de trois racines d'angélique pharmacopéiques ont été identifiés et leurs profils de métabolites ont été corrélés à l'activité pharmacologique, avec des structures clés responsables de la modulation de la sécrétion d’insuline. Pour certaines métabolites le mécanisme d'action a été étudié. Les métabolites végétaux actifs pourraient ainsi devenir des structures de référence dans la recherche de nouveaux traitements antidiabétiques, qui devraient être plus amplement évalués.
- 5 June 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Effects and underlying mechanism of plant secondary metabolites on insulin secretion regulation
Effets et mécanisme d'action de métabolites secondaires des plantes sur la régulation de la sécrétion d’insuline: Le diabète de type 2 (DT2) est une maladie associant résistance à l'insuline et dysfonction des cellules β pancréatiques. Basées sur la compréhension actuelle de la physiopathologie de cette maladie, différentes approches thérapeutiques ont été développées afin d'améliorer le contrôle glycémique et de ralentir la progression de la maladie. Néanmoins, elles présentent une efficacité limitée et de nombreux effets indésirables. Dans ce contexte, les extraits végétaux et leurs constituants actifs sont considérés comme un domaine important pour la recherche de nouveaux traitements antidiabétiques. Cette thèse avait pour objectif de trouver une source naturelle de métabolites secondaires végétaux potentiellement capables de protéger la fonction des cellules β, d'induire la sécrétion d'insuline de façon gluco-dépendante, et de caractériser le mécanisme d'action des molécules actives. Vingt extraits de plantes ont été profilés phytochimiquement à l'aide de LC-MS, conduisant à l'identification et l'isolement de 39 composés purifiés. Les flavonoïdes, les lignanes et les coumarines ont été testés pour leur capacité à moduler la fonction des cellules β sur le modèle cellulaire INS-1. Certains flavonoïdes et coumarines ont augmenté la sécrétion d'insuline induite par le glucose, tandis qu'aucun effet n'a été observé avec les lignanes. Le mécanisme d'action des métabolites actifs a ensuite été étudié en évaluant leurs effets sur l'activité électrique des cellules, les niveaux de calcium intracellulaire et les courants calciques et potassiques. De plus, l'activité insulino-sécrétoire a été confirmée dans des extraits pharmacopéiques contenant des coumarines. Ces découvertes pourraient avoir des implications sur l'utilisation traditionnelle des racines d'angélique dans le traitement du DT2. Des effets insulinotropes de trois racines d'angélique pharmacopéiques ont été identifiés et leurs profils de métabolites ont été corrélés à l'activité pharmacologique, avec des structures clés responsables de la modulation de la sécrétion d’insuline. Pour certaines métabolites le mécanisme d'action a été étudié. Les métabolites végétaux actifs pourraient ainsi devenir des structures de référence dans la recherche de nouveaux traitements antidiabétiques, qui devraient être plus amplement évalués.
- Open Access
- 26 September 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (1) , 52-68
The flavonoid resokaempferol improves insulin secretion from healthy and dysfunctional pancreatic β‐cells
Background and Purpose: The pharmacology of flavonoids on β‐cell function is largely undefined especially in the context of defective secretion of insulin. We sought to identify flavonoids that increased the insulin‐secreting function of β‐cells and to explore the underlying mechanisms.Experimental Approach: INS‐1 β‐cells in culture and islets of Langerhans isolated from control and diabetic male rats were used for insulin secretion experiments. Pharmacological and electrophysiological approaches were used for mechanistic studies.Key Results: Among a set of flavonoids, exposure of INS‐1 β‐cells to resokaempferol (ResoK) enhanced glucose‐stimulated insulin secretion and therefore we further characterised its activity and its pharmacological mechanism. ResoK glucose‐dependently enhanced insulin secretion in INS‐1 β‐cells and pancreatic islets isolated from rats. Mechanistically, whole cell patch clamp recordings in INS‐1 cells showed that ResoK rapidly and dose‐dependently enhanced the L‐type Ca2+ current whereas it was inactive towards T‐type Ca2+ current. Accordingly, pharmacological inhibition of L‐type Ca2+ current but not T‐type Ca2+ current blocked the effects of ResoK on glucose‐stimulated insulin secretion. ResoK was still active on dysfunctional β‐cells as it ameliorated glucose‐stimulated insulin secretion in glucotoxicity‐induced dysfunctional INS‐1 cells and in pancreatic islets isolated from diabetic rats.Conclusion and Implications: ResoK is a glucose‐dependent activator of insulin secretion. Our results indicated that the effects of ResoK on insulin secretion involved its capacity to stimulate L‐type Ca2+ currents in cultured β‐cells. As ResoK was also effective on dysfunctional β‐cells, our work provides a new approach to stimulating insulin secretion, using compounds based on the structure of ResoK.
- 26 September 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 182 (1) , 52-68
Open AccessThe flavonoid resokaempferol improves insulin secretion from healthy and dysfunctional pancreatic β‐cells
Background and Purpose: The pharmacology of flavonoids on β‐cell function is largely undefined especially in the context of defective secretion of insulin. We sought to identify flavonoids that increased the insulin‐secreting function of β‐cells and to explore the underlying mechanisms.Experimental Approach: INS‐1 β‐cells in culture and islets of Langerhans isolated from control and diabetic male rats were used for insulin secretion experiments. Pharmacological and electrophysiological approaches were used for mechanistic studies.Key Results: Among a set of flavonoids, exposure of INS‐1 β‐cells to resokaempferol (ResoK) enhanced glucose‐stimulated insulin secretion and therefore we further characterised its activity and its pharmacological mechanism. ResoK glucose‐dependently enhanced insulin secretion in INS‐1 β‐cells and pancreatic islets isolated from rats. Mechanistically, whole cell patch clamp recordings in INS‐1 cells showed that ResoK rapidly and dose‐dependently enhanced the L‐type Ca2+ current whereas it was inactive towards T‐type Ca2+ current. Accordingly, pharmacological inhibition of L‐type Ca2+ current but not T‐type Ca2+ current blocked the effects of ResoK on glucose‐stimulated insulin secretion. ResoK was still active on dysfunctional β‐cells as it ameliorated glucose‐stimulated insulin secretion in glucotoxicity‐induced dysfunctional INS‐1 cells and in pancreatic islets isolated from diabetic rats.Conclusion and Implications: ResoK is a glucose‐dependent activator of insulin secretion. Our results indicated that the effects of ResoK on insulin secretion involved its capacity to stimulate L‐type Ca2+ currents in cultured β‐cells. As ResoK was also effective on dysfunctional β‐cells, our work provides a new approach to stimulating insulin secretion, using compounds based on the structure of ResoK.
- 4 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 329, 118133
Pharmacological and phytochemical insights on the pancreatic β-cell modulation by Angelica L. roots
- 4 April 2024
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 329, 118133
Pharmacological and phytochemical insights on the pancreatic β-cell modulation by Angelica L. roots
- Open Access
- 26 July 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (3) , 64-68
Efficacy of satralizumab therapy in the treatment of NMOSD
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affecting the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2022. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD. Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.
- 26 July 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (3) , 64-68
Open AccessEfficacy of satralizumab therapy in the treatment of NMOSD
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affecting the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2022. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD. Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system and is associated with the presence of autoantibodies to anti–aquaporin-4 (AQP4-IgG). Interleukin-6 plays a key role in the pathogenesis of this disorder. Satralizumab, a humanized monoclonal antibody, targets the interleukin-6 receptor thus affects the course of the disease. In Poland, satralizumab treatment has been offered free of charge by the public health service since November 2021. The results of SAkura studies demonstrate the long terms efficacy of satralizumab and provide evidence that satralizumab reduces the risk of relapse in patients with aquaporin-4-immunoglobulin G (IgG)–seropositive (AQP4-IgG+) NMOSD.
- Open Access
- 26 July 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (3) , I-II
Twenty years of Prospects in Pharmaceutical Sciences: recent changes
Prospects in Pharmaceutical Sciences (fka. Bulletin of the Faculty of Pharmacy of the Medical University of Warsaw) is an open access scientific journal, published since 2003 as a quarterly by the Medical University of Warsaw. Prospects in Pharmaceutical Sciences offers immediate Open Access to its publications, permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, free of any charge. The journal does not charge authors fees for submission, editorial process, APC or any other fees. Prospects in Pharmaceutical Sciences is free for both authors and readers. This year we mark its 20th anniversary. Here we present recent changes in the official Journal of the Faculty of Pharmacy of the Medical University of Warsaw.
- 26 July 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (3) , I-II
Open AccessTwenty years of Prospects in Pharmaceutical Sciences: recent changes
Prospects in Pharmaceutical Sciences (fka. Bulletin of the Faculty of Pharmacy of the Medical University of Warsaw) is an open access scientific journal, published since 2003 as a quarterly by the Medical University of Warsaw. Prospects in Pharmaceutical Sciences offers immediate Open Access to its publications, permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, free of any charge. The journal does not charge authors fees for submission, editorial process, APC or any other fees. Prospects in Pharmaceutical Sciences is free for both authors and readers. This year we mark its 20th anniversary. Here we present recent changes in the official Journal of the Faculty of Pharmacy of the Medical University of Warsaw.
- Open Access
- 13 April 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (2) , 68-72
Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland
Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder caused by a genetic mutation in the Survival of motor neuron 1 (SMN1) gene, which is responsible for the production of a protein essential to motor neurons’ survival. Insufficient levels of the SMN protein lead to the loss of motor neurons in the spinal cord, which manifests in progressive muscle wasting. Due to the absence of an effective treatment in the early years, the disease was taking its toll with the respiratory problems being the primary cause of death. Currently, there are multiple approved treatments for SMA, which help to manage the symptoms and to prevent complications, such as nusinersen, risdiplam, and onasemnogene abeparvovec. In Poland, nusinersen treatment has been offered free of charge by the public health service since 2019. It was not until September 2022 that the reimbursement procedure included the other two drugs. The recently published studies on the nusinersen treatment in Poland showed stabilization or slowdown in the progression of symptoms in all patients. In March 2022, Poland implemented an SMA screening program for newborns, which aimed to detect this fatal and disabling disease before the infant displayed any SMA symptoms. The program resulted so far in early diagnosis and intervention providing a better prognosis for patients. Combination of newborn screening and the drug reimbursement program has significantly increased the chances of SMA patients for effective treatment. Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder caused by a genetic mutation in the Survival of motor neuron 1 (SMN1) gene, which is responsible for the production of a protein essential to motor neurons’ survival. Insufficient levels of the SMN protein lead to the loss of motor neurons in the spinal cord, which manifests in progressive muscle wasting. Due to the absence of an effective treatment in the early years, the disease was taking its toll with the respiratory problems being the primary cause of death. Currently, there are multiple approved treatments for SMA, which help to manage the symptoms and to prevent complications, such as nusinersen, risdiplam, and onasemnogene abeparovec. In Poland, nusinersen treatment has been offered free of charge by the public health service since 2019. It wasn’t until September 2022 that the reimbursement procedure included the other two drugs. The recently published studies on the nusinersen treatment in Poland showed stabilization or slowdown in the progression of symptoms in all patients. In March 2022, Poland implemented an SMA screening program for newborns, which aimed to detect this fatal and disabling disease before the infant displayed any SMA symptoms. The program resulted so far in early diagnosis and intervention providing a better prognosis for patients. Combination of newborn screening and the drug reimbursement program has significantly increased the chances of SMA patients for effective treatment.
- 13 April 2023
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 21 (2) , 68-72
Open AccessSpinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland
Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder caused by a genetic mutation in the Survival of motor neuron 1 (SMN1) gene, which is responsible for the production of a protein essential to motor neurons’ survival. Insufficient levels of the SMN protein lead to the loss of motor neurons in the spinal cord, which manifests in progressive muscle wasting. Due to the absence of an effective treatment in the early years, the disease was taking its toll with the respiratory problems being the primary cause of death. Currently, there are multiple approved treatments for SMA, which help to manage the symptoms and to prevent complications, such as nusinersen, risdiplam, and onasemnogene abeparvovec. In Poland, nusinersen treatment has been offered free of charge by the public health service since 2019. It was not until September 2022 that the reimbursement procedure included the other two drugs. The recently published studies on the nusinersen treatment in Poland showed stabilization or slowdown in the progression of symptoms in all patients. In March 2022, Poland implemented an SMA screening program for newborns, which aimed to detect this fatal and disabling disease before the infant displayed any SMA symptoms. The program resulted so far in early diagnosis and intervention providing a better prognosis for patients. Combination of newborn screening and the drug reimbursement program has significantly increased the chances of SMA patients for effective treatment. Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular disorder caused by a genetic mutation in the Survival of motor neuron 1 (SMN1) gene, which is responsible for the production of a protein essential to motor neurons’ survival. Insufficient levels of the SMN protein lead to the loss of motor neurons in the spinal cord, which manifests in progressive muscle wasting. Due to the absence of an effective treatment in the early years, the disease was taking its toll with the respiratory problems being the primary cause of death. Currently, there are multiple approved treatments for SMA, which help to manage the symptoms and to prevent complications, such as nusinersen, risdiplam, and onasemnogene abeparovec. In Poland, nusinersen treatment has been offered free of charge by the public health service since 2019. It wasn’t until September 2022 that the reimbursement procedure included the other two drugs. The recently published studies on the nusinersen treatment in Poland showed stabilization or slowdown in the progression of symptoms in all patients. In March 2022, Poland implemented an SMA screening program for newborns, which aimed to detect this fatal and disabling disease before the infant displayed any SMA symptoms. The program resulted so far in early diagnosis and intervention providing a better prognosis for patients. Combination of newborn screening and the drug reimbursement program has significantly increased the chances of SMA patients for effective treatment.
- Open Access
- 13 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3750
Bio-Guided Isolation of Compounds from Fraxinus excelsior Leaves with Anti-Inflammatory Activity
Inflammation is the first physiological defence mechanism against external and internal stimuli. The prolonged or inappropriate response of the immune system may lead to the persistent inflammatory response that can potentially become a basis for chronic diseases e.g., asthma, type II diabetes or cancer. An important role in the alleviation of inflammatory processes, as an adjunct to traditional pharmacological therapy, is attributed to phytotherapy, especially to raw materials with a long tradition of use, e.g., ash leaves. Despite their long-term use in phytotherapy, the specific mechanisms of action have not been confirmed in a sufficient number of biological or clinical studies. The aim of the study is a detailed phytochemical analysis of infusion and its fractions, isolation of pure compounds from the leaves of Fraxinus excelsior and evaluation of their effect on the secretion of anti-inflammatory cytokines (TNF-α, IL-6) and IL-10 receptor expression in an in vitro model of monocyte/macrophage cells isolated from peripheral blood. Methods: Phytochemical analysis was carried out by the UHPLC-DAD-ESI-MS/MS method. Monocytes/macrophages were isolated from human peripheral blood using density gradient centrifugation on Pancoll. After 24 h incubation with tested fractions/subfractions and pure compounds, cells or their supernatants were studied, respectively, on IL-10 receptor expression by flow cytometry and IL-6, TNF-α, IL-1β secretion by the ELISA test. Results were presented with respect to Lipopolysaccharide (LPS) control and positive control with dexamethasone. Results: The infusion, 20% and 50% methanolic fractions and their subfractions, as well as their dominating compounds, e.g., ligstroside, formoside and oleoacteoside isolated from the leaves, show the ability to increase the IL-10 receptor expression on the surface of monocyte/macrophage cells, stimulated by LPS, and to decrease the secretion of pro-inflammatory cytokines, e.g., TNF-α, IL-6.
- 13 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (4) , 3750
Open AccessBio-Guided Isolation of Compounds from Fraxinus excelsior Leaves with Anti-Inflammatory Activity
Inflammation is the first physiological defence mechanism against external and internal stimuli. The prolonged or inappropriate response of the immune system may lead to the persistent inflammatory response that can potentially become a basis for chronic diseases e.g., asthma, type II diabetes or cancer. An important role in the alleviation of inflammatory processes, as an adjunct to traditional pharmacological therapy, is attributed to phytotherapy, especially to raw materials with a long tradition of use, e.g., ash leaves. Despite their long-term use in phytotherapy, the specific mechanisms of action have not been confirmed in a sufficient number of biological or clinical studies. The aim of the study is a detailed phytochemical analysis of infusion and its fractions, isolation of pure compounds from the leaves of Fraxinus excelsior and evaluation of their effect on the secretion of anti-inflammatory cytokines (TNF-α, IL-6) and IL-10 receptor expression in an in vitro model of monocyte/macrophage cells isolated from peripheral blood. Methods: Phytochemical analysis was carried out by the UHPLC-DAD-ESI-MS/MS method. Monocytes/macrophages were isolated from human peripheral blood using density gradient centrifugation on Pancoll. After 24 h incubation with tested fractions/subfractions and pure compounds, cells or their supernatants were studied, respectively, on IL-10 receptor expression by flow cytometry and IL-6, TNF-α, IL-1β secretion by the ELISA test. Results were presented with respect to Lipopolysaccharide (LPS) control and positive control with dexamethasone. Results: The infusion, 20% and 50% methanolic fractions and their subfractions, as well as their dominating compounds, e.g., ligstroside, formoside and oleoacteoside isolated from the leaves, show the ability to increase the IL-10 receptor expression on the surface of monocyte/macrophage cells, stimulated by LPS, and to decrease the secretion of pro-inflammatory cytokines, e.g., TNF-α, IL-6.
- Open Access
LC-DAD–ESI-MS/MS and NMR Analysis of Conifer Wood Specialized Metabolites
Many species from the Pinaceae family have been recognized as a rich source of lignans, flavonoids, and other polyphenolics. The great common occurrence of conifers in Europe, as well as their use in the wood industry, makes both plant material and industrial waste material easily accessible and inexpensive. This is a promising prognosis for both discovery of new active compounds as well as for finding new applications for wood and its industry waste products. This study aimed to analyze and phytochemically profile 13 wood extracts of the Pinaceae family species, endemic or introduced in Polish flora, using the LC-DAD–ESI-MS/MS method and compare their respective metabolite profiles. Branch wood methanolic extracts were phytochemically profiled. Lignans, stilbenes, flavonoids, diterpenes, procyanidins, and other compounds were detected, with a considerable variety of chemical content among distinct species. Norway spruce (Picea abies (L.) H.Karst.) branch wood was the most abundant source of stilbenes, European larch (Larix decidua Mill.) mostly contained flavonoids, while silver fir (Abies alba Mill.) was rich in lignans. Furthermore, 10 lignans were isolated from the studied material. Our findings confirm that wood industry waste materials, such as conifer branches, can be a potent source of different phytochemicals, with the plant matrix being relatively simple, facilitating future isolation of target compounds.
Open AccessLC-DAD–ESI-MS/MS and NMR Analysis of Conifer Wood Specialized Metabolites
Many species from the Pinaceae family have been recognized as a rich source of lignans, flavonoids, and other polyphenolics. The great common occurrence of conifers in Europe, as well as their use in the wood industry, makes both plant material and industrial waste material easily accessible and inexpensive. This is a promising prognosis for both discovery of new active compounds as well as for finding new applications for wood and its industry waste products. This study aimed to analyze and phytochemically profile 13 wood extracts of the Pinaceae family species, endemic or introduced in Polish flora, using the LC-DAD–ESI-MS/MS method and compare their respective metabolite profiles. Branch wood methanolic extracts were phytochemically profiled. Lignans, stilbenes, flavonoids, diterpenes, procyanidins, and other compounds were detected, with a considerable variety of chemical content among distinct species. Norway spruce (Picea abies (L.) H.Karst.) branch wood was the most abundant source of stilbenes, European larch (Larix decidua Mill.) mostly contained flavonoids, while silver fir (Abies alba Mill.) was rich in lignans. Furthermore, 10 lignans were isolated from the studied material. Our findings confirm that wood industry waste materials, such as conifer branches, can be a potent source of different phytochemicals, with the plant matrix being relatively simple, facilitating future isolation of target compounds.
- Open Access
Extraction Techniques and Analytical Methods for Isolation and Characterization of Lignans
Lignans are a group of natural polyphenols present in medicinal plants and in plants which are a part of the human diet for which more and more pharmacological activities, such as antimicrobial, anti-inflammatory, hypoglycemic, and cytoprotective, are being reported. However, it is their cytotoxic activities that are best understood and which have shed light on this group. Two anticancer drugs, etoposide, and teniposide, were derived from a potent cytotoxic agent—podophyllotoxin from the roots of Podophyllum peltatum. The evidence from clinical and observational studies suggests that human microbiota metabolites (enterolactone, enterodiol) of dietary lignans (secoisolariciresinol, pinoresinol, lariciresinol, matairesinol, syringaresinol, medioresinol, and sesamin) are associated with a reduced risk of some hormone-dependent cancers. The biological in vitro, pharmacological in vivo investigations, and clinical studies demand significant amounts of pure compounds, as well as the use of well-defined and standardized extracts. That is why proper extract preparation, optimization of lignan extraction, and identification are crucial steps in the development of lignan use in medicine. This review focuses on lignan extraction, purification, fractionation, separation, and isolation methods, as well as on chromatographic, spectrometric, and spectroscopic techniques for their qualitative and quantitative analysis.
Open AccessExtraction Techniques and Analytical Methods for Isolation and Characterization of Lignans
Lignans are a group of natural polyphenols present in medicinal plants and in plants which are a part of the human diet for which more and more pharmacological activities, such as antimicrobial, anti-inflammatory, hypoglycemic, and cytoprotective, are being reported. However, it is their cytotoxic activities that are best understood and which have shed light on this group. Two anticancer drugs, etoposide, and teniposide, were derived from a potent cytotoxic agent—podophyllotoxin from the roots of Podophyllum peltatum. The evidence from clinical and observational studies suggests that human microbiota metabolites (enterolactone, enterodiol) of dietary lignans (secoisolariciresinol, pinoresinol, lariciresinol, matairesinol, syringaresinol, medioresinol, and sesamin) are associated with a reduced risk of some hormone-dependent cancers. The biological in vitro, pharmacological in vivo investigations, and clinical studies demand significant amounts of pure compounds, as well as the use of well-defined and standardized extracts. That is why proper extract preparation, optimization of lignan extraction, and identification are crucial steps in the development of lignan use in medicine. This review focuses on lignan extraction, purification, fractionation, separation, and isolation methods, as well as on chromatographic, spectrometric, and spectroscopic techniques for their qualitative and quantitative analysis.
- Open Access
- 17 August 2022
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 20 (2) , 24-30
Isolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L.
Trachelogenin 4-O-β-D-glucoside or tracheloside is a rare lignan glycoside present mostly in some plants from the Cynarae tribe of the Asteraceae family. As this lignan is also present in small amounts in the human diet, isolation and study of the pharmacological properties of this compound may bring some new insights into the role of lignans. This study aimed to isolate trachelogenin 4-O-β-D-glucoside from the fruits of safflower using chromatographic methods. Briefly, 339 mg of tracheloside was isolated from 500 g of plant material. The yield is sufficient for performing biological studies, thus confirming that safflower fruits are a significant source of this rare compound.
- 17 August 2022
- Published by Warszawski Uniwersytet Medyczny in Prospects in Pharmaceutical Sciences
- Vol. 20 (2) , 24-30
Open AccessIsolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L.
Trachelogenin 4-O-β-D-glucoside or tracheloside is a rare lignan glycoside present mostly in some plants from the Cynarae tribe of the Asteraceae family. As this lignan is also present in small amounts in the human diet, isolation and study of the pharmacological properties of this compound may bring some new insights into the role of lignans. This study aimed to isolate trachelogenin 4-O-β-D-glucoside from the fruits of safflower using chromatographic methods. Briefly, 339 mg of tracheloside was isolated from 500 g of plant material. The yield is sufficient for performing biological studies, thus confirming that safflower fruits are a significant source of this rare compound.